Intra-Cellular Therapies Inc. (ITCI) Financials
ITCI Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 728.3 million | 136.9 million |
2023-09-30 | 717.7 million | 117.0 million |
2023-06-30 | 713.6 million | 106.5 million |
2023-03-31 | 722.2 million | 94.5 million |
ITCI Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -2.1 million | 14.9 million |
2023-09-30 | -25.5 million | 14.3 million |
2023-06-30 | -36.8 million | 13.2 million |
2023-03-31 | -60.1 million | 10.4 million |
ITCI Net Income
No data available :(
ITCI Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 497.9 million | - | 16.9 million |
2023-09-30 | 493.0 million | - | 17.5 million |
2023-06-30 | 512.9 million | - | 18.0 million |
2023-03-31 | 538.7 million | - | 18.5 million |
ITCI Shares Outstanding
ITCI Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 1000 | 50.8 million | 104.7 million | - |
2023-09-30 | 268000 | 41.6 million | 105.2 million | - |
2023-06-30 | - | 49.8 million | 101.0 million | - |
2023-03-31 | - | 38.0 million | 98.9 million | - |
ITCI Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 131.5 million | 10.7 million |
2023-09-30 | 125.8 million | 9.1 million |
2023-06-30 | 110.1 million | 7.2 million |
2023-03-31 | 94.7 million | 6.8 million |
ITCI
Price: $67
52 week price:
Earnings Per Share: -1.46 USD
P/E Ratio: -44.44
Exchange: NMS
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 307914
Ebitda: -22.8 millionMarket Capitalization: 7.3 billion